nausea; fever; chills; arm pain at vaccination site; dose 1: 03nov2021 and dose 2: 26feb2022; this is a spontaneous report received from a contactable reporter (consumer) from the regulatory authority (ra). regulatory number: gb-mhra-webcovid-202202270801318190-es8sa. other case identifier(s): gb-mhra-adr 26657087. a 12 year-old female patient received bnt162b2 (comirnaty), administration date 26feb2022 (lot number: fm3092) at the age of 12 years as dose 2, single for covid-19 immunisation. the patient's relevant medical history and concomitant medications were not reported. vaccination history included: comirnaty (dose 1, single; lot number: unknown), administration date: 03nov2021, for covid-19 immunisation. the following information was reported: nausea (medically significant) with onset 26feb2022, outcome "recovering", described as "nausea"; pyrexia (medically significant) with onset 26feb2022, outcome "not recovered", described as "fever"; chills (medically significant) with onset 26feb2022, outcome "recovering", described as "chills"; vaccination site pain (medically significant) with onset 26feb2022, outcome "unknown", described as "arm pain at vaccination site"; inappropriate schedule of product administration (non-serious) with onset 26feb2022, outcome "unknown", described as "dose 1: 03nov2021 and dose 2: 26feb2022". the clinical course was reported as follows: the patient had arm pain at vaccination site occurred from an hour after vaccination. nausea, fever and chills occurred about 12-14 hours after vaccination. the patient had no symptoms associated with covid-19 and did not undergo a covid-19 test. the patient was not enrolled in clinical trial. the patient was not tested positive for covid-19 since the vaccination. the report of the patient was not related to possible inflammation of the heart (myocarditis or pericarditis). no follow-up attempts are possible. no further information is expected